Quest Diagnostics Incorporated
DGX
Kedudukan dalam Saham
#929
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus,... Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Harga Saham
$236.69
Modal Pasaran
$26.12B
Perubahan (1 hari)
0.80%
Perubahan (1 tahun)
24.31%
Negara
US
Perdagangan Quest Diagnostics Incorporated (DGX)
Kategori
Healthcare
Nisbah P/E bagi Quest Diagnostics Incorporated (DGX)
Nisbah P/E pada October 2026 TTM: 24.47
Menurut laporan kewangan dan harga saham terkini Quest Diagnostics Incorporated, nisbah P/E semasa (TTM) ialah 24.47. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 19.23.
Sejarah nisbah P/E bagi Quest Diagnostics Incorporated dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 24.47 | 26.00% |
| 2025 | 19.42 | 1.00% |
| 2024 | 19.23 | 6.32% |
| 2023 | 18.08 | -5.74% |
| 2022 | 19.18 | 76.96% |
| 2021 | 10.84 | -2.86% |
| 2020 | 11.16 | -33.09% |
| 2019 | 16.68 | 8.39% |
| 2018 | 15.39 | -11.97% |
| 2017 | 17.48 | -12.38% |
| 2016 | 19.95 | 38.06% |
| 2015 | 14.45 | -17.38% |
| 2014 | 17.49 | 82.45% |
| 2013 | 9.59 | -42.36% |
| 2012 | 16.63 | -15.06% |
| 2011 | 19.58 | 48.85% |
| 2010 | 13.15 | -14.56% |
| 2009 | 15.40 | -11.24% |
| 2008 | 17.35 | -42.32% |
| 2007 | 30.07 | 68.91% |
| 2006 | 17.80 | -6.40% |
| 2005 | 19.02 | -2.47% |
| 2004 | 19.50 | 12.55% |
| 2003 | 17.33 | 1.71% |
| 2002 | 17.04 | -58.67% |
| 2001 | 41.22 | -33.82% |
| 2000 | 62.28 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 36.15 | 47.76% |
US
|
|
| 39.77 | 62.55% |
US
|
|
| -290.26 | -1,286.24% |
US
|
|
| - | - |
CN
|
|
| 34.18 | 39.71% |
US
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.